DOVAUnknown
Dova Pharmaceuticals Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Dova Pharmaceuticals Inc. (DOVA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are DOVA insiders buying or selling?
Dova Pharmaceuticals Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2018, Trabud has recorded 38 Form 4 filings for DOVA: 23 buys ($25.5M) and 15 sells ($872.0K).
Source: SEC EDGAR Form 4
Key Statistics (June 2018 – Oct 2, 2019)
Total Form 4 filings
38
SEC EDGAR
Insider filers
11
Insider buys (23)
$25.5M
Insider sells (15)
$872.0K
Insider sentiment
Net buyingNet insider flow of $24.6M in net buying since June 2018.
Recent DOVA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2019 | David Zaccardelli | President & CEO | Sale | 5.3K | $27.90 | $147.2K | SEC ↗ |
| Oct 2, 2019 | Phd F Allen Lee MD | Chief Medical Officer | Sale | 978 | $28.00 | $27.4K | SEC ↗ |
| Oct 2, 2019 | Mark W Hahn | Chief Financial Officer | Sale | 775 | $28.00 | $21.7K | SEC ↗ |
| Oct 2, 2019 | Jason Hoitt | Chief Commercial Officer | Sale | 2.4K | $28.00 | $66.8K | SEC ↗ |
| Oct 2, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sale | 3.7K | $28.00 | $103.5K | SEC ↗ |
| Sep 27, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sale | 3.1K | $20.00 | $62.0K | SEC ↗ |
| Aug 12, 2019 | Manning Paul B | Director, 10% Owner | Purchase | 28.1K | $15.87 | $445.3K | SEC ↗ |
| Aug 1, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sale | 1.4K | $15.97 | $22.2K | SEC ↗ |
| Jul 16, 2019 | Jason Hoitt | Chief Commercial Officer | Sale | 7.6K | $15.26 | $115.7K | SEC ↗ |
| Jul 12, 2019 | Joseph Edelman | 10% Owner | Purchase | 85.1K | $16.68 | $1.4M | SEC ↗ |
| Jul 9, 2019 | Joseph Edelman | 10% Owner | Purchase | 50.0K | $16.46 | $823.0K | SEC ↗ |
| Jul 4, 2019 | Joseph Edelman | 10% Owner | Purchase | 20.5K | $14.51 | $298.0K | SEC ↗ |
| Jul 3, 2019 | David Zaccardelli | President & CEO | Sale | 10.4K | $15.94 | $166.6K | SEC ↗ |
| Jul 2, 2019 | Mark W Hahn | Chief Financial Officer | Sale | 1.5K | $14.17 | $21.9K | SEC ↗ |
| Jul 2, 2019 | Roger Jeffs | Director | Sale | 1.3K | $14.17 | $18.5K | SEC ↗ |
| Jul 2, 2019 | Kevin Laliberte | Sr. VP, Product Development | Sale | 1.2K | $14.17 | $16.9K | SEC ↗ |
| Jul 2, 2019 | Phd F Allen Lee MD | Chief Medical Officer | Sale | 2.0K | $14.19 | $27.8K | SEC ↗ |
| Jul 2, 2019 | Jason Hoitt | Chief Commercial Officer | Sale | 2.4K | $13.81 | $33.0K | SEC ↗ |
| Jul 1, 2019 | Joseph Edelman | 10% Owner | Purchase | 427.2K | $13.35 | $5.7M | SEC ↗ |
| Apr 10, 2019 | Jason Hoitt | Chief Commercial Officer | Sale | 2.4K | $8.77 | $20.9K | SEC ↗ |
| Mar 8, 2019 | Manning Paul B | Director, 10% Owner | Purchase | 68.0K | $7.48 | $508.6K | SEC ↗ |
| Dec 21, 2018 | Roger Jeffs | Director | Purchase | 30.0K | $6.22 | $186.6K | SEC ↗ |
| Dec 21, 2018 | David Zaccardelli | President & CEO | Purchase | 10.0K | $6.07 | $60.7K | SEC ↗ |
| Dec 21, 2018 | Manning Paul B | Director, 10% Owner | Purchase | 128.5K | $6.48 | $832.1K | SEC ↗ |
| Dec 21, 2018 | John A Stalfort III | Director | Purchase | 31.0K | $6.26 | $194.1K | SEC ↗ |
Showing the 25 most recent of 38 Form 4 filings for Dova Pharmaceuticals Inc..
Most active DOVA insiders
- Joseph Edelman10 filings
- Manning Paul B6 filings
- Jason Hoitt4 filings
- Kevin Laliberte4 filings
- David Zaccardelli3 filings
Ask anything about DOVA insider activity
Use Trabud's AI agent to query Dova Pharmaceuticals Inc.'s Form 4 history in plain English — "Show me DOVA CEO purchases this year" or compare it against any other ticker.
Open the AI agentDOVA insider trading FAQ
Are Dova Pharmaceuticals Inc. insiders buying or selling?
Dova Pharmaceuticals Inc. insiders reported no open-market purchases or sales in the last 12 months. Since June 2018, Trabud has recorded 38 Form 4 filings for DOVA: 23 buys ($25.5M) and 15 sells ($872.0K). Over the full record that is net buying of $24.6M.
How many insiders trade DOVA stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Dova Pharmaceuticals Inc.. The most recent filing was accepted on Oct 2, 2019.
Where does Trabud get DOVA insider trading data?
All DOVA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.